BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Hong Kong's Akeso Receives FDA IND Clearance for AK117 in MDS Combo with Azacitidine

The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States. Based on th...

September 29, 2023 | News

Mabwell Starts Phase Ib/II Trial for Nectin-4 ADC with PD-1 Inhibitor

The clinical trial (CTR20232677) is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 9MW2821 in combination with ...

September 29, 2023 | News

OBiO Launches GMP Facility Intelli-M for Rapid Delivery of Innovative Therapies

The launch of the new base in Shanghai will enhance OBiO's production and service capabilities in both China and the United States...

September 28, 2023 | News

Kivo launches unified platform offering best-in-class collaboration and compliance solution

Kivo GO is a new, unified platform for emerging life sciences companies who need to manage documents and processes across their Regulatory, Clinical and ...

September 27, 2023 | News

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design

Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design...

September 27, 2023 | News

Ascletis Completes Enrollment for Glioblastoma Treatment Trial

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ...

September 27, 2023 | News

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

"We're thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based technology has been gra...

September 26, 2023 | News

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to disco...

September 22, 2023 | News

Asieris Pharmaceuticals' APL-1702 Achieves Key Milestone in Cervical HSIL Treatment Trial

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs fo...

September 21, 2023 | News

SomaLogic and Korea’s DNA Link Join Forces to Expand SomaScan® Platform in Asia-Pacific Proteomics Market

SomaLogic Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, announced its partnership with DNA Link, an innovator in personalized a...

September 20, 2023 | News

China's NMPA Recommends Priority Review for Cefepime-Taniborbactam in UTI Treatment

"Currently, the clinical challenges from multi-drug resistant infections are severe. The recommendation of priority review by CDE for cefepime-taniborbacta...

September 20, 2023 | News

Caliway Completes Recruitment for CBL-514 Cellulite Treatment Phase 2 Study

The CBL-0201EFP Phase 2-stage 2 study is an open-label trial that will evaluate the efficacy, safety, and tolerability of CBL-514 in treating subjects with...

September 20, 2023 | News

Breaking Barriers to Health Equity: Empowering Clinical Trial Access in Asia

Clinical trials play a pivotal role in advancing medical knowledge and improving healthcare outcomes. However, a significant challenge in a...

September 13, 2023 | Analysis

Menarini Asia-Pacific and Astellas Sign Exclusive Licensing Deal for Smyraf® in Taiwan and SE Asian Markets

Subject to the terms of the agreement, Astellas will receive total payments of up to €5.5 million including upfront and milestone payments. In additio...

September 13, 2023 | News

Stay Connected